Comparative Pharmacology
Head-to-head clinical analysis: BECLOMETHASONE DIPROPIONATE versus VANCERIL DOUBLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BECLOMETHASONE DIPROPIONATE versus VANCERIL DOUBLE STRENGTH.
BECLOMETHASONE DIPROPIONATE vs VANCERIL DOUBLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through binding to glucocorticoid receptors, leading to inhibition of phospholipase A2, reduced prostaglandin and leukotriene synthesis, and suppression of inflammatory cytokines.
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced arachidonic acid release, and decreased synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, adhesion molecule expression, and eosinophil survival, thereby reducing airway inflammation.
Inhalation: 40-320 mcg twice daily (DPI or pMDI); maximum 640 mcg/day. Intranasal: 1-2 sprays (42-84 mcg) per nostril twice daily. Topical: Apply 0.025% cream/ointment twice daily.
2 inhalations (168 mcg beclomethasone dipropionate) twice daily via oral inhalation.
None Documented
None Documented
Clinical Note
moderateBeclomethasone dipropionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gatifloxacin."
Clinical Note
moderateBeclomethasone dipropionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rosoxacin."
Clinical Note
moderateBeclomethasone dipropionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is 2.8-3.1 hours after inhalation, with a slower phase attributed to slow dissolution from lung tissue; clinical context: supports twice-daily dosing.
Terminal elimination half-life: 1.5–2 hours for beclomethasone dipropionate; 2.7 hours for active metabolite beclomethasone-17-monopropionate. Clinical context: supports twice-daily dosing.
Primarily fecal (via bile) as metabolites, ~60-70%; renal excretion accounts for <10% of unchanged drug.
Primarily hepatic metabolism; metabolites excreted renally (~90% as free and conjugated metabolites) and fecally (<10%).
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid
Beclomethasone dipropionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trovafloxacin."